3月3日 - ** 药物开发商Protagonist Therapeutics PTGX.O股价盘前上涨9%至41美元
** PTGX和武田4502.T称， (link)，其治疗一种血癌的药物在一项晚期研究中达到了患者反应比例的主要目标。
** 该公司称，77%的患者对该药物（芦非肽）产生了反应，而接受安慰剂治疗的患者比例为33%。
** 该药物在患有罕见血癌--多发性红细胞症--的病人中进行了测试，这些病人需要定期抽取血液(phlebotomy) 来控制病情。
** 公司称，与服用安慰剂的患者相比，没有证据表明服用芦伐他汀的患者罹患癌症的风险会增加
** PTGX 在过去 12 个月中上涨了 23.5
(为便利非英文母语者，路透将其报导自动化翻译为数种其他语言。由于自动化翻译可能有误，或未能包含所需语境，路透不保证自动化翻译文本的准确性，仅是为了便利读者而提供自动化翻译。对于因为使用自动化翻译功能而造成的任何损害或损失，路透不承担任何责任。)
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.